Embryonic stem cell therapy-heart failure - Asterias Biotherapeutics

Drug Profile

Embryonic stem cell therapy-heart failure - Asterias Biotherapeutics

Alternative Names: CM-1; GRNCM 1

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Geron Corporation
  • Developer Asterias Biotherapeutics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Heart failure

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Heart-failure in USA (Intracoronary, Implant)
  • 10 Aug 2015 BioTime has patent protection for the manufacturing method of cardiomyocytes from human embryonic stem cells
  • 26 Jan 2015 BioTime receives patent allowance for Stem ell technology in Europe, Canada, China, Singapore, Australia and Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top